Skip to main content
Premium Trial:

Request an Annual Quote

MDMA, New Hampshire Contingent Join Opposition to Patent Reform Act

NEW YORK (GenomeWeb News) — The Medical Devices Manufacturers Association and a private-public New Hampshire-based contingent last week joined the growing list of organizations opposing the Patent Reform Act of 2007, currently under bi-cameral review in the US Congress.
 
In a letter sent to key members of the House and Senate Judiciary Committees, MDMA representatives said that the Act would “hinder innovation across the diverse sectors of the American economy we represent, including academia, agriculture, alternative energy, biotechnology, chemical, electronics, environmental technology, financial services, information technology, life sciences, nanotechnology, and telecommunications.”
 
The letter highlights three shared areas of concern: language pertaining to the apportionment of damages, the creation of an open-ended post-grant review process, and the granting of unprecedented rulemaking authority for the US Patent and Trademark Office.
 
Other signatories of the letter include the Biotechnology Industry Organization, Innovation Alliance, NanoBusiness Alliance, CropLife America, Association of University Technology Managers, Institute of Electrical and Electronics Engineers, Small Business Technology Council, and Center for Small Business and the Environment.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.